Posts by Sandra Ansanay-Alex
MindMaze Announces a CHF 8.0 Million Equity Financing with Neuro.io
MindMaze Therapeutics Holding SA, a Lausanne-based global leader in scalable precision neurotherapeutics, announces it has entered into a definitive agreement for a CHF 8.0 million equity financing with Neuro.io Group SA, through which Neuro.io will acquire a strategic equity position in the company. The proceeds will support the company’s commercial priorities, including scaling its U.S.…
Read MoreA New Humanoid Robotics School in Renens
Asinov School — School of Embodied Intelligence — will open its doors in September 2026 in Renens, within UniverCité/Station R innovation ecosystem in the canton of Vaud. Students will be trained in building humanoid robots for healthcare, industry, logistics, and services. The initiative is a joint venture between the Dalle Molle Foundation, the Inartis Foundation…
Read MoreInside TRB Chemedica: a visit to one of Valais’ quiet pharmaceutical powerhouses
Tucked away in Vouvry, in the Swiss canton of Valais, TRB Chemedica is the kind of company that rarely makes headlines yet quietly supplies patients around the world. A delegation from Swiss Valley recently had the opportunity to tour the site, discover its manufacturing processes, and walk the prefilled-syringe filling lines first-hand. The company specialises…
Read MoreHAYA Therapeutics doses first cohort in Phase 1 trial of a precision therapy for cardiac fibrosis
Swiss-American biotech HAYA Therapeutics has dosed the first cohort in the Phase 1 clinical trial of HTX-001, its lead investigational therapy and a first-in-class candidate aimed at the underlying fibrosis that drives heart disease. HTX-001 is an antisense oligonucleotide designed to downregulate WISPER, a heart stress-specific long non-coding RNA (lncRNA) that is overexpressed in patients…
Read MoreINSIDE – Biofactory Competence Center
Join the Swiss Health Valley community for a BioAlps’ INSIDE event, at Biofactory Competence Center – Fribourg (FR) from 3.30 pm to 5.30 pm on 3 June 2026. Since its founding in 2015, the Biofactory Competence Center (BCC) in Fribourg is a unique biopharmaceutical training and research institution in Switzerland and part of HEIA-FR, the…
Read MoreSwiss Biotool Startup Bionomous Launches Sortivo
Swiss biotool startup Bionomous has launched Sortivo™, an automated benchtop platform for the gentle screening, sorting, and plating of complex biological entities — a step the company says will help labs adopt New Approach Methodologies (NAMs), the non-animal alternatives increasingly favoured by regulators. Sortivo handles delicate biological entities ranging from roughly 300 μm to 2…
Read MoreNeurosoft Bioelectronics Closes $7.5M Oversubscribed Seed Round
Geneva-based neurotechlogy company Neurosoft Bioelectronics announces that it has raised a $7.5 million oversubscribed seed financing round. Headquartered in Campus Biotech with a US presence in New York, the company is developing a scalable and soft brain-computer interfaces (BCIs). The funds will be used to advance clinical trials across both the United States and Europe.…
Read MoreThe GenPK Project Receives CHF 3,5 millions from FNS
The Jules Gonin Eye Hospital, the CHUV and the University of Lausanne are to study the genomes of 12,000 people from highly consanguineous families in Pakistan in order to improve the detection of risks associated with developing rare diseases. The Swiss National Science Foundation has awarded a funding of CHF 3,494,000 to Dr Muhammad Ansar,…
Read MoreInvestors & Innovators × JLABS Accelerator
On Wednesday, May 13th, at Campus Biotech Geneva, BioAlps welcomed Elena Fernandez Kleinlein and Michael Huebner of Johnson & Johnson Innovation / JLABS Accelerator for an afternoon of close-up encounters with some of the most promising neurotech and biotech ventures emerging from the Swiss Health Valley. The visit followed a morning at Biopole in Lausanne…
Read MoreDr Andrea Pfeifer Retires From AC Immune
AC Immune SA, a Lausanne-based clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, announces that Dr Andrea Pfeifer has decided to retire from her role as Chief Executive Officer (CEO) of AC Immune, after 23 years of tenure, at the upcoming Annual General Meeting (AGM) to spend more time with her family. Dr Pfeifer…
Read More